The present invention relates to compounds of general formula (I) in particular for use in the treatment of senescence-related diseases, such as idiopathic pulmonary fibrosis, sarcopenia, diabetes, obesity, osteoarthritis, chronic inflammation, glaucoma, cataracts, radiation-induced oral mucosis, renal transplantation, prostatic hyperplasia.

##STR00001##

Provided herein are organic long persistent luminescence compositions and methods of use and preparation thereof and articles comprising the same.

The invention relates to the chemical synthesis of oligonucleotides, e.g., oligoribonucleotides. In another aspect, the invention relates to compounds of formula (II): ##STR00001##
processes for making these compounds, and the use thereof in the chemical synthesis of oligonucleotides, e.g., oligoribonucleotides. The invention also relates to methods of synthesis of oligomers, including but not limited to oligopeptides, oligosaccharides and oligonucleotides, particularly oligoribonucleotides and also oligodeoxyribonucleotides, in solution systems, and ionic tag linkers for use in methods provided herein.

The present invention relates to compounds of general formula (I) in particular for use in the treatment of senescence-related diseases, such as idiopathic pulmonary fibrosis, sarcopenia, diabetes, obesity, osteoarthritis, chronic inflammations, glaucoma, cataracts, radiation-induced oral mucosis, renal transplantation, prostatic hyperplasia. ##STR00001##

The invention provides compounds of Formula (I), or pharmaceutically acceptable salts thereof:

##STR00001##

The compounds, compositions, methods and kits of the invention are useful for the treatment of pain, itch, and neurogenic inflammation.

The invention provides compounds of Formula (I), or pharmaceutically acceptable salts thereof:

##STR00001##

The compounds, compositions, methods and kits of the invention are useful for the treatment of pain, itch, and neurogenic inflammation.

Heteroatomic hole transport materials are provided. The hole transport materials include a non-carbon core: two, four, or eight aromatic groups covalently bound to the non-carbon core; a. terminal substituted diphenylamine end unit on each aromatic group: and optionally aromatic linker groups linking the aromatic groups and the substituted diphenylamine end units. In some embodiments the non-carbon core is non-carbon central atom such as Si, Ge, B.sup., P.sup.+Sn or Pb. In other embodiments, the non-carbon core is a cubic silsesquioxane. Also provided are methods for making these materials. The materials are particularly useful as hole transport materials in perovskite solar cells.

The present invention provides mito-honokiol or mito-magnolol compounds, pharmaceutical compositions thereof, and methods of using the mito-honokiol or mito-magnolol compounds in the treatment of cancer.

The invention provides novel zwitterionic monomers and polymers (including copolymers) with pendent phosphonium-based zwitterionic moieties, and compositions and products comprising same, as well as related methods and uses of the compositions, for example, as surfactants, coatings, and interlayer materials, biomedical materials or agents.

The invention relates to a process for preparing triaryl organo borates proceeding from organoboronic esters in the presence of an n-valent cation 1/n K.sup.n+, comprising the anhydrous workup of the reaction mixture and the use of the triaryl organoborates obtained as co-initiator in photopolymer formulations, holographic media and holograms.